Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma
Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma
Immunohistochemical detection of the BRAF-V600E mutation on pre-operative fine needle
 aspiration biopsy (FNAB) from patients suspected for papillary thyroid carcinoma, using the
 mutation specific antibody VE1.
The BRAF mutation is reported to be present in approximately 50% of papillary thyroid
 carcinomas (PTC). The mutation has been associated with poor prognosis and more advanced
 disease stage. Therefore, pre-operative detection of the BRAF-V600E mutation may be of
 clinical interest in order to individualize treatment of patients with BRAF positive PTC.

 FNABs are performed immediately before the thyroid operation, and BRAF-V600E detection using
 VE1 is performed on clots. The VE1 stain is compared to the mutation status of the removed
 cancer or control tissue using the Cobas test.
Inclusion Criteria:

 -  Bethesda system of reporting thyroid cytology (BSRTC) group 5-6 on pre-operative FNAB
 from the nodule (>1cm)

 -  Undergoing thyroid surgery (histology of index nodule)

 Exclusion Criteria:

 -  Not undergoing thyroid surgery